Scarica l'app Stockscreener
0.2824
1.74%
-0.005
Dopo l'orario di chiusura:
.29
0.0076
+2.69%
Precedente Chiudi:
$0.2874
Aprire:
$0.275
Volume 24 ore:
509.75K
Relative Volume:
0.50
Capitalizzazione di mercato:
$10.09M
Reddito:
-
Utile/perdita netta:
$-12.29M
Rapporto P/E:
-0.2716
EPS:
-1.0399
Flusso di cassa netto:
$-9.07M
1 W Prestazione:
-2.28%
1M Prestazione:
-16.94%
6M Prestazione:
-74.79%
1 anno Prestazione:
-77.94%
Intervallo 1D:
$0.275
$0.304
Intervallo di 1 settimana:
$0.2701
$0.315
Portata 52W:
$0.2178
$1.73
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Nome
Akari Therapeutics Plc Adr
Settore
Industria
Telefono
(929) 274-7510
Indirizzo
401 EAST JACKSON STREET, TAMPA
Confronta AKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
0.2824 | 10.27M | 0 | -12.29M | -9.07M | -1.0399 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Iniziato | Ladenburg Thalmann | Buy |
| 2025-07-18 | Iniziato | Maxim Group | Buy |
| 2019-01-04 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-09-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2017-05-31 | Aggiornamento | Chardan Capital Markets | Sell → Neutral |
| 2017-04-17 | Reiterato | Chardan Capital Markets | Sell |
| 2016-07-11 | Iniziato | Chardan Capital Markets | Sell |
Mostra tutto
Akari Therapeutics Plc Adr Borsa (AKTX) Ultime notizie
Akari Therapeutics to Present at the 2026 Biotech Showcase - Chartmill
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Sahm
Akari Therapeutics Plc ADR (AKTX) Stock Sees a-0.57% Decrease - News Heater
Akari Therapeutics advances ADC oncology program with novel payload By Investing.com - Investing.com South Africa
Akari Therapeutics advances ADC oncology program with novel payload - Investing.com India
Operating cash flow per share of Akari Therapeutics Plc Sponsored ADR – FWB:CLA - TradingView — Track All Markets
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Expands By 650.6% - Defense World
Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com
Akari begins GMP manufacturing of lead ADC program with WuXi XDC By Investing.com - Investing.com South Africa
Akari Therapeutics Releases Virtual Investor “What This Means” Segment - Sahm
Akari Therapeutics (Nasdaq: AKTX) sells 10M ADSs and issues new warrants - Stock Titan
Akari Therapeutics raises $5 million in at-market offering By Investing.com - Investing.com South Africa
Akari Therapeutics raises $5 million in at-market offering - Investing.com India
Akari Therapeutics stock rises on promising pancreatic cancer drug data By Investing.com - Investing.com South Africa
Akari Therapeutics stock rises on promising pancreatic cancer drug data - Investing.com
Views of Wall Street’s Leading Experts on Moderna Inc - setenews.com
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment - Sahm
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance - Investing.com
Akari Therapeutics receives Nasdaq notice for minimum bid price non-compliance By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Release of the Next CEO Corner Segment - Sahm
Tops & Flops Stocks - sharewise.com
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer - Finviz
Akari Therapeutics appoints Kameel Farag as interim CFO By Investing.com - Investing.com South Africa
Akari Therapeutics appoints Kameel Farag as interim CFO - Investing.com
[DEF 14A] Akari Therapeutics Plc Definitive Proxy Statement - Stock Titan
[S-1] Akari Therapeutics Plc Files IPO Registration Statement | AKTX SEC FilingForm S-1 - Stock Titan
Insiders Re-Evaluate Their US$1.81m Stock Purchase As Akari Therapeutics Falls To US$19m - Sahm
Why Akari Therapeutics Plc Depositary Receipt stock appeals to analystsWall Street Watch & Verified Momentum Stock Watchlist - newser.com
[PRE 14A] Akari Therapeutics Plc Preliminary Proxy Statement - Stock Titan
Akari Therapeutics Plc ADR (AKTX) looking to reclaim success with recent performance - setenews.com
Akari Therapeutics forms scientific advisory board with Dr. Hurvitz By Investing.com - Investing.com South Africa
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP - The Manila Times
What Wall Street predicts for Akari Therapeutics Plc Depositary Receipt stock priceMarket Performance Summary & Weekly Breakout Stock Alerts - newser.com
Akari Therapeutics launches CEO Corner to enhance investor communications By Investing.com - Investing.com India
Form 424B5 Akari Therapeutics Plc - StreetInsider
Akari Therapeutics stock falls after $2.5 million registered offering - Investing.com
Akari Therapeutics secures $2.5 million through registered offering - Investing.com India
$2.5M raise: Akari Therapeutics to issue 3,125,000 ADSs in registered direct offering - Stock Titan
Akari Therapeutics files new patents for cancer treatment technology - Investing.com India
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 - Sahm
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
Will Akari Therapeutics Plc (Common Stock) (CLA) stock beat revenue estimatesWeekly Profit Analysis & Weekly Market Pulse Alerts - newser.com
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Sahm
A new trading data show Core Scientific Inc (CORZ) is showing positive returns. - Setenews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Akari’s ADC payload shows promise against resistant prostate cancer By Investing.com - Investing.com South Africa
Akari’s ADC payload shows promise against resistant prostate cancer - Investing.com India
First Potential Treatment for AR-V7 Driven Prostate Cancer: Akari's PH1 Shows Dual Action in Studies - Stock Titan
Akari Therapeutics Plc Adr Azioni (AKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):